Werfen announced their commendation for the recent publication of a significant, multi-author Special Report, underscoring the urgent need to address the risks of undetected in vitro hemolysis, a preanalytical error with the potential to negatively impact patient care.
The Company congratulated the authors on this important and timely publication.
Published in the Journal of Applied Laboratory Medicine (JALM)—an international, peer-reviewed publication—the Special Report, "Handling Hemolytic Blood Samples from High-Risk Clinical Areas: A Call to Action," advocates for a coordinated, hospital-wide approach to better detect, prevent, and manage in vitro hemolysis, particularly in high-risk settings, such as emergency departments and intensive care units. The report highlights hemolysis as a significant cause of preanalytical error, with the potential to cause misinterpretation of critical results, most notably potassium.
This Special Report reinforces the problem of in vitro hemolysis, emphasizes the need for hemolysis detection in whole blood and provides six recommendations as a call to action to address this significant preanalytical error.
Read Werfen's announcement here
